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Abstract  
Objective: We determined outcomes and risks of intravenous thrombolysis (IVT) in patients 
with acute ischemic stroke (AIS) over 80-years within 3hr compared to >3-4.5hr recorded in 
the SITS International Stroke Thrombolysis registry. 
 
Methods: 14,240 (Year 2003-2015) patients >80 years with AIS were treated with IVT ≤4.5h 
of stroke onset (3,558 in >3-4.5hr).  Of these 8658 (2157 in >3-4.5hr) were treated otherwise 
according to the European Summary of product criteria (EU-SmPC) for alteplase. Outcomes 
were 3-month functional independence (modified Rankin scale 0–2), mortality, and 
symptomatic intracerebral hemorrhage (SICH)/SITS. Results were compared between the >3-
4.5hr and <=3hr patients.   
 
Results:  Median age was 84 years, 61% female in both groups. Median NIHSS was 12 vs. 14 
in the >3-4.5hr and <=3hr respectively. Three-month functional independence was 34% vs. 
35%, adjusted odds ratio (aOR, 95% CI) 0.78 (0.69-0.89, p<0.001). Mortality 31% vs. 32%, 
aOR 1.10 (0.97-1.25, p=0.13), SICH/SITS 2.7% vs. 1.6%, aOR 1.72 (1.25-2.35, p=0.001). In 
EU-SmPC compliant patients: Three-month functional independence was 36 vs. 37%, aOR 
0.79 (0.68-0.92, p=0.002). Mortality 29% vs. 29.6%, aOR 1.10 (0.95-1.28, p=0.20). 
SICH/SITS 2.7% vs. 1.6%, aOR 1.62(1.12-2.34, p=0.01). 
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Conclusions: In this observational study, unselected patients >80-years treated with IVT after 
3h versus earlier had a slightly higher rate of SICH but similar unadjusted functional outcome 
but poorer adjusted outcome. The absolute difference between the treatment groups is small 
and elderly patients should not be denied IVT in the later time window solely for age without 
other contraindications. 
 
Main text: 
 
Introduction 
 
Pooled analysis of randomized controlled trials (RCTs) of intravenous thrombolysis (IVT) for 
acute ischemic stroke has shown that patients >80 years treated with IVT versus control 
derived equal benefit compared to patients 18-80 years. Within the >3-4.5h window the effect 
was significant for younger patients (OR 1.26 [1.04-1.54]) but was not independently 
significant for the more elderly;  however, the elderly sample was smaller and showed a 
greater point estimate (OR 1.36 [0.87-2.14]).1 Effectiveness of IVT diminished as the 
treatment delay increased across the first 6 hours without a corresponding increase in the 
relative risk of symptomatic intracerebral hemorrhage (SICH).1 Real world registry 
experience supports these RCT data in patients >80 years treated within 3h.2,3 The SITS-ISTR 
(Safe Implementation of Treatment in Stroke-International Stroke Thrombolysis Register)-
VISTA analysis demonstrated benefit of IVT in patients >80 years compared to control and 
found no difference in the slope of benefit versus treatment delay for younger versus elderly 
patients,3 a finding that was confirmed in the RCT dataset.4   
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The European guideline5 recommends use of IVT within 4.5h of symptom onset also in the 
elderly, but North American guidance does not recommend IVT in the >3-4.5h window in 
patients >80 years.6 Most European regulatory agencies have not approved marketing of IVT 
with Actilyse for use in ischemic patients >80 years, whereas the American regulatory agency 
supports promotion of IVT in patients >80 years within 3h of symptom onset.  
 
About 30% of admitted ischemic stroke patients are older than 80 years7,8 but about 2/3 
of overall stroke-related morbidity and mortality occurs in patients >80 years old.9,10 A large 
proportion of these elderly patients are possible candidates for thrombolysis. Divergent 
recommendations from professional bodies and regulatory agencies may have a 
negative impact on IVT treatment in elderly populations. 
 
We used the SITS-ISTR to determine the outcomes and risks of IVT that are achieved in 
routine practice in patients >80 years in the >3-4.5h compared to within 3h time window.  
 
Methods: 
Study design: 
This is an observational study based on retrospective analysis of a prospective registry. 
Patient selection: 
Figure 1 shows the flow diagram for patient selection. In the primary analysis, we 
included unselected ischemic stroke patients over 80 years who were treated with 
intravenous alteplase within 4.5 hours of symptoms onset and registered in SITS-
ISTR between 2003 and 2015.11 Patients treated with mechanical thrombectomy, 
unknown or missing stroke onset to treatment time were excluded from the analysis. In 
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the sensitivity analysis, we only included patients treated in compliance with the other 
European Summary of Product Characteristics criteria (EU SmPC). European licence 
restrictions of intravenous alteplase in acute ischemic stroke described in the EU 
SmPC.12 In light of these, the following data were collected in the SITS-ISTR, and we 
excluded them from the sensitivity analysis: 1) Severe stroke as assessed clinically (e.g. 
NIHSS>25) and/or by appropriate imaging techniques, 2) Administration of heparin 
within the previous 48 hours and a thromboplastin time exceeding the upper limit of 
normal for laboratory, 3) Patients with any history of prior stroke and concomitant 
diabetes, 4) Prior stroke within the last 3 months, 5) Systolic blood pressure >185 
mmHg or diastolic blood pressure >110 mmHg, or aggressive management (IV 
medication) necessary to reduce BP to these limits, 6) Blood glucose <50 or > 400 
mg/dl (<2.7 or > 22.2 mmol/L), 7) Patients receiving oral anticoagulants, e.g. warfarin 
sodium. 
 
We collected baseline and demographic characteristics including stroke severity using 
the National Institutes of Health Stroke Scale (NIHSS), and pre-stroke disability using 
the modified Rankin Scale (mRS), medication at stroke onset, risk factors, NIHSS at 2, 
24 hours and 7 days following treatment, brain imaging prior to IVT treatment and 
follow up CT brain imaging at 24-36 hours and any other extra imaging scans to assess 
for hemorrhagic transformation, and mRS at 3 months.  
 
Ethical considerations and source data verification 
The need for ethical approval or patient consent for participation in SITS-ISTR varied among 
participating countries, but approvals were obtained in countries that required this; other 
countries approved the register for conduct as an anonymized audit. The current study is a 
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part of the SITS-Monitoring Study II which is approved by the Ethics Committee of the 
Karolinska Institute in Stockholm, Sweden.  
The SITS International Coordination Office performed regular online monitoring of the SITS-
ISTR data and checked individual patient data on a regular basis to handle errors or 
inconsistencies. For a sample of patients included in SITS-MOST (n=6483)8, source data 
were verified on-site by monitors under the supervision of their national coordinator.  
Outcome measurements 
Main outcome measurements 
Functional 
independence at 3 
months 
modified Rankin Scale Score (mRS) score of 2 at 3 months 
Symptomatic 
intracerebral 
hemorrhage (SICH) per 
the SITS-MOST13 
a local or remote parenchymal hemorrhage type 2 on the 22- to 36-
h post-treatment imaging scan or earlier if clinically indicated, 
combined with a neurological worsening of 4 points in the NIHSS 
score between baseline and 24 h, or leading to death.  
SICH per the ECASS-
214 
Any intracerebral hemorrhage on any post-treatment imaging scans 
combined with NIHSS worsening 4 points between baseline and 
7days (ECASS definition).  
For comparison with other published work, we also analyzed the following outcomes 
No/ minimal disability mRS score 0 or 1 at 3 months 
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SICH per the NINDS15 Any intracerebral hemorrhage on any post-treatment imaging scans 
combined with any decline in neurologic status as measured by 
NIHSS between baseline and 7days. 
Death Death within 3 months 
Hemorrhagic 
transformation (HT) 
was categorized using the ECASS trial definitions.14  
 
All evaluations of imaging studies and neurological status were performed according to 
clinical routine by the local sites. All definitions of SICHs were adjudicated by the SITS 
International Coordination Office based on the clinical and imaging data entered by the 
investigators in the registry.  
Statistical analysis   
In the primary analysis, patients over 80yrs were divided into two groups according to stroke 
onset to treatment time (OTT): IVT initiated within 3h (the early cohort) and in the >3-4.5h 
(the later cohort). Descriptive statistics for the baseline and demographic data were contrasted 
according to the early and the later cohort per OTT.  Unknown or missing values were 
excluded from the denominator when calculating proportions. Hemorrhagic transformations, 
SICH, neurological status until day 7 or discharge and 90 day mortality and disability (mRS) 
were compared between the two groups.  We performed multivariable logistic regression 
analyses to examine if the outcomes differ between the two OTT groups after adjusting for 
baseline imbalances. Unknown or missing values were excluded from the multivariable 
analysis. We performed sensitivity analysis for patients treated in compliance with the other 
European Summary of Product Characteristics criteria (EU SmPC). The following variables 
were entered into the multivariable model as a predictor for outcome parameters based on 
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their statistical significance in the univariate analysis at 10% level and known clinical 
importance to predict outcome even if p>0.10:  age, sex, baseline NIHSS, history of DM, 
hypertension, smoking, previous stroke within 3m, atrial fibrillation and pre-stroke mRS, 
signs of current infarction, hyperdense artery sign, systolic blood pressure and plasma glucose. 
Hospital arrival to treatment time was not included in the model due to collinearity with onset 
to treatment time. P-values less then 5% were regarded as statistical significance. All analyses 
were performed using STATISTICA software, version 13.  
 
Results: 
Between January 2003 and December 2015, 14240 patients over 80 years with acute ischemic 
stroke treated with IVT within 4.5h of symptom onset were recorded in the SITS-ISTR. These 
patients were recorded from 45 countries across 595 centers and 94% (n=13370) were from 
European countries. Patients treated within the 3-4.5h time window were registered from 38 
countries across 399 clinical centers.  
 
Baseline and demographic characteristics of patients over 80 years treated with IVT within 3-
4.5h are compared with ≤3h of symptom onset in Table 1. In the later cohort, median time for 
IVT initiation was longer (83 minutes since stroke onset and 25 minutes since hospital arrival) 
and median stroke severity was lower (by 2 points as measured by NIHSS score) compared to 
the early cohort.  
Figure 2 (Table e-1) shows the extent of hemorrhage found on any post-IVT imaging scans. 
The overall rate of HT was 19.1% vs. 16.1% (p=0.0001) in the later compared to the early 
time window. Patients who received IVT in the later cohort had slightly higher local type of 
hemorrhages compared to the early cohort (p=0.0001 for overall difference between the 
groups). When tested within each hemorrhage type separately, HI1 (p=0.03) and PH2 
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(p<0.0001) appeared statistically significant between the groups. There was no difference 
regarding remote hemorrhages between later and early cohorts (p=0.5). In patients treated 
within EU SmPC criteria, overall rate of HT was 18.1% vs. 15.7% (p=0.01), any PHs was 
9.6% vs. 8.1% (p=0.03), any local hemorrhages 16.1% vs. 13.6% (p=0.005), remote 
hemorrhages 3.5% vs. 3.7% (p=0.52) in the later compared to the early time window 
respectively. 
 
In Table 2 main outcome results were compared between early and later cohorts. Patients 
>80 years treated in the later time window had a higher frequency of SICH in the univariate 
analysis and higher adjusted odds ratio in the multivariable analysis compared to patients 
treated earlier. Patients >80 years treated in the later time window had a similar rate of 
functional outcome in the univariate analysis but had a lower odds ratio for functional 
independence in the multivariable analysis compared to patients treated in the early time 
window. Mortality at 3 months did not differ statistically significantly between the early and 
later time windows in the univariate or multivariate analysis. 
 
Figure 3 shows the distribution of mRS at 3-months categorized by stroke onset to treatment 
time 
 
Patients compliant with the other European Summary of Product Characteristics 
criteria (EU SmPC) 
In the Table e-2, baseline and demographic characteristics of patients over 80 years treated 
with IVT in compliance with the other EU SmPC criteria were compared between early and 
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later cohorts.  
In the Table 3 main outcome results were compared between later and early cohorts for 
patients in compliance with the other EU SmPC criteria. Results were similar for the EU 
SmPC cohort as for the unselected cohort described above but the overall outcomes in the EU 
SmPC cohort were better than the unselected cohort in both time windows. 
 
Patients with missing 3 months mRS 
In the Table e-3 (supplementary), baseline and demographic characteristic of patients for 
missing 3m outcome data were compared between the early and later time window. There 
was no statistically significant difference between the early and later time window patients 
with regard to baseline characteristics except for higher frequency of previous stroke >3m 
earlier (16% vs. 12%, p=0.01), oral antihypertensive treatment (72% vs. 68%, p=0.03), 
plasma glucose (6.8 vs. 6.6 mmol/L, p=0.047), longer hospital arrival to treatment time (82 vs. 
59 min, p<0.001) and lower NIHSS (11 vs. 13, p<0.001) score in the later compared to early 
time window respectively.  
 
Discussion: 
This study with a large number of acute ischemic stroke patients over 80 years old treated 
with IVT showed slightly higher frequency and adjusted odds ratio (aOR) of SICH in the later 
time window (>3-4.5h) compared to earlier time window (<=3h). The overall rate of 
hemorrhagic transformations (HTs) was also higher in the later compared to earlier time 
window. We did not detect a difference in SICH or overall HT rates between early and later 
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cohorts in our first SITS >3-4.5h publication among the patients aged up to 80 years.16 The 
current study findings are consistent with a subsequent analysis of  SITS in a larger cohort of 
EU SmPC-compliant patients aged up to 80 years, which found higher rates of SICH per SITS 
in the >3-4.5h compared to 3h time window.17 In a recent prospective study, SICH per 
ECASS 2 (aOR 1.46, p=0.05) and NINDS (aOR 1.35, p=0.07) were borderline significantly 
higher in the later time window compared to early time window. 18  
 
In the pooled analysis of RCTs, there was no hint that HTs and SICH rates increase in the 
later treatment window (>3h) compared to earlier time window (<=3h). The overall fatal 
intracranial hemorrhage rate was higher (3.6% vs. 2.3%) in the >80 years compared to <=80 
years. The smaller pooled analysis population has not published an analysis of patients older 
than 80 years and treated >3h.1 We do not know if the higher HTs and SICH in the >3-4.5h 
time window observed in our study applies only for IVT treated patients or is a natural 
phenomenon in control and IVT treated patients, as we lack a control group.  
 
Post-thrombolysis imaging scans were performed 81 minutes later from stroke onset (25.6h in 
the 3h vs. 26.9h in the >3-4.5h) in our study cohort which may have contributed slightly 
higher rates of visible HTs in the later than early cohort. A possible relation between onset to 
assessment time and SICH rate that is independent of treatment was apparent in the control 
group of the pooled RCT, published by STTC.4 The absolute incidence of SITS-MOST 
hemorrhage was 0.4% <3h, 0.6% >3-4.5h and 0.7% >4.5h, though the small numbers do not 
permit reliable estimation, and stratification by age groups was not performed.  
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In the unadjusted analysis, frequency of functional outcome (mRS 0-2 and mRS 0-1) and 
mortality at 3 months was similar between the >3-4.5h and ≤3h time windows. In the 
multivariable analyses, adjusted odds ratios were significantly lower for functional outcome 
(mRS 0-2 and mRS 0-1) at 3 months in the >3-4.5h compared to ≤3h but odds ratio for 
mortality did not differ significantly between the groups. The difference between unadjusted 
and adjusted analysis for functional outcome at 3 months could partly be explained by less 
severe stroke in the >3-4.5h group (2 points lower median NIHSS) compared to the 3h group. 
However, patients treated in the >3-4.5h time window had some higher prevalence of 
characteristics associated with worse outcome specifically higher pre-stroke functional 
dependency, DM, previous smoking, anti-hypertensive treatment, signs of current infarction 
in the imaging scans, plasma glucose. Most importantly longer stroke onset to treatment time 
is one of the powerful predictors of poor outcome after thrombolysis and yet defines the 
distinction between the 3-4.5h versus <= 3h cohorts. Pre-stroke disability may have been 
underestimated. The reliability of premorbid mRS assessment may be questioned, when 
undertaken rapidly in elderly patients who are less likely to have reliable witnesses on hand 
and when treatment options may be known to be influenced by admission of disability; delay 
in reaching hospital after acute stroke may be associated with such premorbid disability. 
These and other unidentified imbalances may have contributed poor outcome despite our 
efforts to achieve appropriate statistical adjustment for imbalances in the multivariable 
analyses.  
In the sensitivity analysis for patients treated according to the other EU SmPC, the results are 
similar compared to unselected population. The current study results in EU SmPC patients are 
in line with previous SITS publications where we compared outcome between early and later 
time window in patients ≤80 years who were compliant with the EU SmPC.16-19 There, the 
outcomes were poorer among patients treated in the later time window. It is also important to 
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note that the statistical significance will be heavily driven by the large sample size. Although 
SICH rate was higher in the later than early time window, the absolute difference between the 
groups was small (ranging between 1.1% and 1.8% depending on the definition of SICH):  
these differences may not be clinically significant, since elderly patients generally have poor 
outcome if untreated.  
 
Our study has several limitations. Important limitations are observational design and lack of a 
control group without IVT treatment. There are some baseline imbalances between the groups 
which may bias the study results. The statistically significant baseline differences between the 
groups are probably not clinically relevant since they differ in the range 1-3% and became 
statistically significant due to the large sample size. Baseline stroke severity was 2 points 
lower and hospital arrival to treatment time was 25 minutes longer in the later group than 
early group. Although we performed multivariable analysis to adjust for recorded baseline 
differences, this may not account for all imbalances, or may overemphasize the observed 
imbalances. A final limitation is the extent of missing data, in particular 3 months outcome 
data which were missing for about 25% of patients. We analyzed baseline and demographic 
characteristics of these patients with missing data. We did not detect any major imbalance in 
the nature or extent of messiness between the later and earlier time windows, and the affected 
patients appear similar to patients with known outcomes. Nevertheless, this is a major source 
of potential bias that warrants extremely cautious interpretation of the findings. 
 
Ischemic stroke patients over 80 years treated with IVT in the later time window had slightly 
higher SICH and had similar unadjusted functional outcome but poorer outcome when 
adjusted for baseline imbalances in unselected patients compared to patients treated within 3h. 
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The absolute difference between the treatment groups is small and elderly patients should not 
be denied IVT in the later time window solely for age without other contraindications. 
Caution is required to interpret these results that come from an observational, uncontrolled 
registry; similar findings were previously reported for patients aged <=80 years.  
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Table 1 Baseline and clinical characteristics of patients over 80 years by stroke onset to 
treatment time category 
Baseline and demographic 
variables 
Data median (IQR) for continuous or 
ordinal variables or percentage % 
(n/N) for proportions 
OTT <=3h, 
n=10682  
OTT >3-4.5h 
n= 3558 
p-
value 
Age (years) 84 (82-87) 84 (82-87) 0.17 
Sex (female) 61% (6564/10682) 61% (2188/ 3558) 0.96 
Independence (mRS 0-1) before 
stroke 
76% (7560/ 9906) 74 % (2452/ 3303) 0.02 
Hypertension 77% (8021/ 10463) 78% (2732/ 3500) 0.09 
Diabetes Mellitus 18% (1913/ 10464) 21% (727/ 3504) 0.001 
Hyperlipidemia 29% (2939/ 10028) 28% (973/ 3426) 0.32 
Atrial fibrillation 39% (4027/ 10368) 36% (1259/ 3479) 0.005 
Congestive heart failure  14% (1457/10339) 14% (494/ 3464) 0.81 
Previous stroke>3m earlier  14% (1421/ 10350) 14% (497/ 3475) 0.40 
Previous stroke<=3m  2.1% (204/ 9905) 1.6% (54/ 3394) 0.09 
History of transient ischemic attack 8.4% (600/7136) 8.3% (240/2902) 0.85 
Any history of Smoking 16% (1545/9799) 14.4% (480/3327) 0.07 
Aspirin at stroke onset 45% (4704/10412) 44% (1529/ 3475) 0.23 
Dipyridamole 2.3 (240/10463) 2.3% (79/3499) 0.95 
Anti-hypertensive, oral 70% (7279/10430) 74% (2565/ 3481) <0.001 
Anticoagulants, oral 4.5% (434/ 9603) 5.0% (161/ 3191) 0.24 
Blood glucose (mmol/L) 6.7 (5.8-8.1) 6.9 (5.9-8.4) <0.001 
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Weight in kg 70 (60-78) 70 (60-78) 0.51 
rt-PA dose in mg 63 (54-70) 63 (54-70) 0.55 
NIHSS excluding distal motor 
function 
14 (8-19) 12 (7-18) <0.001 
Systolic blood pressure (mm Hg) 156 (140-170) 158 (140-171) 0.08 
Diastolic blood pressure (mm Hg) 80 (70-90) 80 (70-90) 0.001 
Signs of current infarction at imaging 18% (1803/10108) 20% (685/ 3433) 0.006 
Hyperdense artery sign 22.2% (2214/9961) 18.4% (610/3309) <0.001 
Door to treatment time (minutes) 60 (42-82) 85 (55-122) <0.001 
Stroke onset to treatment time 
(minutes) 
132 (105-158) 215 (195-240) <0.001 
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Table 2 Proportion (%) and adjusted odds ratio (OR) of main outcomes in 
patients over 80 years treated in the early compared to the later time window  
 
Outcomes OTT<=3h 
% (n/N) 
OTT 3-4.5h 
% (n/N) 
Absolute 
difference 
of % 
p-value Adjusted OR1 
(95% CI) 
p-value 
SICH per SITS-
MOST 
1.6% 
(161/10127) 
2.7%  
(90/ 3364) 
1.1% 0.0001 1.72 (1.25-2.35) 0.0007 
SICH per 
ECASS-2 
5.4%  
(534/ 9988) 
7.1%  
(235/ 3321) 
1.7% 0.0002 1.43 (1.18-1.74) 0.0003 
SICH per 
NINDS 
8.0%  
(801/ 10044) 
9.8%  
(326/ 3331) 
1.8% 0.001 1.34 (1.13-1.58) 0.0006 
Functional 
Independence at 
3 months  
34.8% 
(2838/8151) 
34.0%  
(903/ 2654) 
0.8% 0.46 0.78 (0.69-0.89) 0.0001 
No/ minimal 
disability at 3 
months 
23.4%  
(1903/ 8151) 
22.5%  
(596/ 2654) 
0.9% 0.36 0.80 (0.69-0.91) 0.001 
Mortality at 3 
months 
32.2% 
(2688/8340) 
31.4%  
(854/ 2721) 
0.8% 0.41 1.10 (0.97-1.25) 0.13 
 
 
                                                        
1 Early time window (<=3h) is the reference group. Multivariable analysis adjusted for age, sex, 
baseline NIHSS, history of DM, hypertension, smoking, previous stroke within 3m, atrial fibrillation 
and pre-stroke mRS, signs of current infarction, hyperdense artery sign, systolic blood pressure and 
plasma glucose.   
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Table 3 Proportion (%) and adjusted odds ratio (OR) of main outcomes in patients over 
80 years treated in the early time window compared to patients treated in the later time 
window compliant with the EU SmPC 
Outcomes OTT<=3h 
% (n/N) 
  
OTT 3-4.5h 
% (n/N) 
 
Absolute 
difference 
of % 
p-
value 
Adjusted OR2 
(95% CI) 
p-
value 
SICH per SITS-
MOST 
1.6%  
(97/ 6278) 
2.7% 
(55/ 2075) 
1.1% 0.001 1.62 (1.12-2.34) 0.01 
SICH per 
ECASS-2 
5.1% 
(314/ 6208) 
6.7% 
(138/ 2052) 
1.6% 0.004 1.38 (1.09-1.75) 0.007 
SITS per 
NINDS 
7.7% 
(478/ 6230) 
9.4% 
(194/ 2058) 
1.7% 0.01 1.27 (1.04-1.55) 0.02 
Functional 
Independence at 
3 months  
37.1% 
(1887/ 5088) 
36.0% 
(601/ 1670) 
1.1% 0.42 0.79 (0.68-0.92) 0.002 
No/ minimal 
disability at 3 
months 
25.4% 
(1291/ 5088) 
24.3% 
(406/ 1670) 
1.1% 0.39 0.78 (0.67-0.92) 0.003 
Mortality at 3 
months 
29.6% 
(1538/ 5194) 
29.0% 
(495/ 1707) 
0.6% 0.63 1.10 (0.95-1.28) 0.20 
 
 
                                                        
2 Early time window (<=3h) is the reference group. Multivariable analysis adjusted for age, sex, 
baseline NIHSS, history of DM, hypertension, smoking, previous stroke earlier than 3m, atrial 
fibrillation and pre-stroke mRS, signs of current infarction, hyperdense artery sign, systolic blood 
pressure and plasma glucose.   
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Figure legends 
Figure 1 Study flow diagram for patient selection. OTT= Stroke onset to treatment time, 
mRS= modified Rankin Scale, SICH= Symptomatic Intracerebral Hemorrhage, EU SmPC= 
European Summary of Product Criteria 
 
Figure 2 Proportions (%) of hemorrhagic transformation on post-thrombolysis imaging 
scans in patients older than 80 years treated in the early and later time window. HI 
(Hemorrhagic Infarct), PH (Primary Intracerebral Hemorrhage), PHr (Remote Primary 
Intracerebral Hemorrhage), EU SmPC (European Summary of Product Criteria), OTT (Onset 
to thrombolysis treatment time) 
 
Figure 3 shows the distribution of mRS (modified Rankin Scale) at 3-months in all patients 
over 80 years and in patients over 80 years treated according to other EU SmPC (European 
Summary of Product Criteria) categorized by stroke onset to treatment time 
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Figure 1 
 
  
Between January 2003 and December 2015, 
14240 patients over 80 years with acute ischemic stroke treated with IVT within 4.5h of 
symptom onset were recorded in the SITS-ISTR 
N=10682 in the OTT <=3h 
N=10127 had SICH data for univariate 
analysis 
N=6661 in the multivariable model for 
SICH after excluding missing/ 
unknown for covariates 
 
N= 3558 in the OTT >3-4.5h 
N=3364 had SICH data for 
univariate analysis 
N=2364 in the multivariable model 
for SICH after excluding missing/ 
unknown for covariates 
 
N= 8151 had 3m outcome data for 
mRS 
N= 5588 were in the final 
multivariable model after excluding 
missing/ unknown for covariates 
 
N= 2654 had 3m outcome data for 
mRS 
N= 2157 were in the in the final 
multivariable model after excluding 
missing/ unknown for covariates 
 
 
N= 5088 had 3m outcome data for 
mRS 
N= 4148 were in the final multivariable 
model after excluding missing/ 
unknown for covariates 
 
N= 1670 had 3m outcome data for 
mRS 
N= 1414 were in the final multivariable 
model after excluding missing/ unknown 
for covariates 
 
8658 patients were otherwise treated according to the EU SmPC criteria 
N= 6501 in the OTT <=3h 
N=6278 had SICH data for univariate 
analysis 
N= 4994 were in the final multivariable 
model for SICH after excluding 
missing/ unknown for covariates 
 
N= 2157 in the OTT >3-4.5h 
N=2075 had SICH data for univariate 
analysis 
N= 1724 in the in the final 
multivariable model for SICH after 
excluding missing/ unknown for 
covariates 
 
 26 
Figure 2 
 
 
Figure 3 
 
